68Ga-PSMA-11 PET/CT in Bilateral Clear Cell Renal Cell Carcinoma: an Intra-patient Comparison Between High and Low Grade Tumors-Reference-Cited by-同舟云学术

68Ga-PSMA-11 PET/CT in Bilateral Clear Cell Renal Cell Carcinoma: an Intra-patient Comparison Between High and Low Grade Tumors

Published:2023-04-24 Issue:6 Volume:57 Page:298-300
ISSN:1869-3474
Container-title:Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Nucl Med Mol Imaging

Author:

Urso Luca^ORCID,Rocca Giovanni Christian,Conti Grazia Maria,Colella Alessandro,Nieri Alberto^ORCID,Cittanti Corrado,Ippolito Carmelo^ORCID,Bartolomei Mirco

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging

Link

https://link.springer.com/content/pdf/10.1007/s13139-023-00805-6.pdf

Reference7 articles.

1. Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148:1299–311.

2. Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med. 2015;29:877–82.

3. Mittlmeier LM, Unterrainer M, Rodler S. Todica & A, Albert NL, Burgard C, et al. 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. Eur J Nucl Med Mol Imaging. 2021;48:2031–7.

4. Urso L, Rocca GC, Uccelli L, Ippolito C, Bartolomei M. 18 F-choline versus 68 Ga-PSMA-11 PET/CT imaging comparison in incidental clear cell renal cell carcinoma. Clin Nucl Med. 2023;48:e178–80.

5. Gaudreault M, Chang D, Hardcastle N, McIntosh L, Jackson P, Kron T, et al. Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging. Clin Transl Radiat Oncol. 2023;40:100608.